Overview

Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer

Status:
Recruiting
Trial end date:
2023-07-30
Target enrollment:
Participant gender:
Summary
This is a phase II, single arm, open-label, single-center study to evaluate the efficacy and safety of Surufatinib combined with Toripalimab in patients with peritoneal metastatic carcinoma of gastrointestinal or primary peritoneal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Peking University